|
Neurogen Corporation - Company Profile Snapshot
| Company Profile: |
Neurogen Corporation |
| Ticker: |
NRGN |
| Exchanges: |
NAS |
| 2008 Sales: |
3,000,000 |
| Major Industry: |
Miscellaneous |
| Sub Industry: |
Medical Services |
| Country: |
UNITED STATES |
| Employees: |
30 |
Business Description
Neurogen Corporation. The Group's principal activities are to discover and develop new drugs for the treatment of neurological, inflammatory, pain and metabolic disorders. Through its Accelerated Intelligent Drug Discovery (TM) platform, it discovers compounds that hit new potential drug targets, evaluates the utility of those targets and optimizes useful leads into new drug candidates. The Group has collaboration agreements with Aventis Pharmaceuticals for the discovery and research of CRF1 receptor-based drugs and collaboration agreement with Merck Sharp & Dohme Limited to research, develop, and commercialize small molecule medicines. It also has a technology transfer agreement with Pfizer Inc. for the licensing and transfer of the Group's proprietary technologies for the discovery of new drugs to Pfizer as well as collaboration agreements for the discovery of GABA-based drugs for anxiety and cognitive disorders.
|
Not the Report you are looking for?
Click here for more browsing options.
|
The following information is available to subscribers or can be accessed by purchasing the Company Profile Report:
|
- Address (mailing), Phone Number, Web Address
- Earnings/Dividends
- Employees
- Exchanges Listed
- Financial Ratio Analysis |
- Recent Stock Performance
- Sales (recent year)
- Senior Officers
- Shareholder Information
- Stock Analysis Summary |
Layout and Content of a Typical Report
|
|
|
|
|
